

Financial news for ARWR dated on 2020-05-13: RBC Capital Initiates Coverage On Arrowhead Pharmaceuticals with Outperform Rating, Announces Price Target of \$62

Financial news for ARWR dated on 2020-05-08: 17 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for ARWR dated on 2020-05-08: Arrowhead Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 sales results.

Financial news for ARWR dated on 2020-05-08: Cantor Fitzgerald Reiterates Overweight on Arrowhead Pharmaceuticals, Lowers Price Target to \$58

Financial news for ARWR dated on 2020-05-07: Arrowhead Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 sales results.

Financial news for ARWR dated on 2020-05-07: Arrowhead Pharmaceuticals Q2 EPS \$(0.200) Misses \$(0.110) Estimate, Sales \$23.528M Beat \$21.740M Estimate

Financial news for ARWR dated on 2020-05-07: The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetrphase Pharma, Dexcom To Join S&P 500

Financial news for ARWR dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for ARWR dated on 2020-05-01: Arrowhead Pharmaceuticals Announces Retirement Of COO Bruce Given

Financial news for ARWR dated on 2020-04-15: Benzinga's Top Upgrades, Downgrades For April 15, 2020

Financial news for ARWR dated on 2020-04-15: Arrowhead Pharmaceuticals shares are trading higher after Cantor Fitzgerald upgraded the stock from Neutral to Overweight and announced a price target of \$60 per share. UPDATE: Shares have since reversed, now lower.

Financial news for ARWR dated on 2020-04-15: Cantor Fitzgerald Upgrades Arrowhead Pharmaceuticals to Overweight, Announces \$60 Price Target

Financial news for ARWR dated on 2020-03-27: Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus package boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.

Financial news for ARWR dated on 2020-03-24: SVB Leerink Upgrades Arrowhead Pharmaceuticals to Market Perform

Financial news for ARWR dated on 2020-03-23: Shares of several healthcare companies are trading lower amid market volatility. Sunday's fiscal stimulus bill failed a procedural senate vote while the Fed Monday morning announced further stimulus measures to support liquidity.

Financial news for ARWR dated on 2020-03-17: Arrowhead Pharma Reports Precautionary Measures To Mitigate Effects Of Coronavirus Spread

Financial news for ARWR dated on 2020-03-17: Goldman Sachs Initiates Coverage On Arrowhead Pharmaceuticals with Neutral Rating, Announces \$45 Price Target

Financial news for ARWR dated on 2020-03-16: Shares of several healthcare companies are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.

Financial news for ARWR dated on 2020-03-13: B. Riley FBR Maintains Buy on Arrowhead Pharmaceuticals, Lowers Price Target to \$57

Financial news for ARWR dated on 2020-03-09: Shares of several healthcare companies are trading lower. Movement appears market-related as markets continue to dip amid the global coronavirus outbreak and OPEC failing to reach production agreement.

Financial news for ARWR dated on 2020-03-09: 52 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for ARWR dated on 2020-03-06: Shares of several healthcare companies are trading lower. Movement appears market related as markets continue to dip amid the global coronavirus outbreak.

Financial news for ARWR dated on 2020-03-03: Arrowhead Pharma Reports Initiation Of Phase 1/2 Study Of ARO-HSD In Normal Healthy Volunteers, Patients with NASH, Suspected NASH

Financial news for ARWR dated on 2020-02-26: Arrowhead Pharmaceuticals shares are trading higher. Not currently seeing company-specific news.

Financial news for ARWR dated on 2020-02-18: 30 Stocks Moving in Tuesday's Pre-Market Session

Financial news for ARWR dated on 2020-02-10: Arrowhead Pharmaceuticals shares are trading higher. Not seeing any company-specific news to justify the price action.

Financial news for ARWR dated on 2020-02-06: The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs

Financial news for ARWR dated on 2020-02-06: Cantor Fitzgerald Maintains Neutral on Arrowhead Pharmaceuticals, Raises Price Target to \$55

Financial news for ARWR dated on 2020-02-05: Arrowhead Pharma Highlights Interim Data On ARO-APOC3, ARO-ANG3

Financial news for ARWR dated on 2020-02-05: Arrowhead Pharmaceuticals Q1 EPS \$(0.03) Misses \$(0.01) Estimate, Sales \$29.45M Miss \$29.5M Estimate

Financial news for ARWR dated on 2020-02-05: The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data

Financial news for ARWR dated on 2020-02-03: Arrowhead Pharmaceuticals shares are trading higher in sympathy with the overall market on a rebound after increased fear of the coronavirus' impact on the economy dropped the Dow roughly 600 points on Friday.

Financial news for ARWR dated on 2020-02-02: The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus

Financial news for ARWR dated on 2020-01-22: 82 Biggest Movers From Yesterday

Financial news for ARWR dated on 2020-01-21: Mid-Afternoon Market Update: CSS Industries Surges Following Acquisition News; Advaxis Shares Slide

Financial news for ARWR dated on 2020-01-21: 55 Stocks Moving In Tuesday's Mid-Day Session

Financial news for ARWR dated on 2020-01-21: Mid-Day Market Update: Dow Falls Over 100 Points; Genprex Shares Spike Higher

Financial news for ARWR dated on 2020-01-21: SVB Leerink Initiates Coverage On Arrowhead Pharmaceuticals with Underperform Rating, Announces \$32 Price Target

Financial news for ARWR dated on 2020-01-21: Arrowhead Pharmaceuticals shares are trading lower. Not seeing any company-specific news to justify the price action.

Financial news for ARWR dated on 2020-01-21: 20 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for ARWR dated on 2019-12-20: Arrowhead Pharma Reports Dosing Of First Patient In AROAAT2002 Open Label Phase 2 Study Of ARO-AAT For Treatment Of Alpha-1 Liver Disease

Financial news for ARWR dated on 2019-12-16: Arrowhead Pharmaceuticals shares are trading lower despite earlier announcement the company has filed an application for approval to begin a Phase 1 clinical trial of ARO-HSD.

Financial news for ARWR dated on 2019-12-16: Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-HSD for Treatment of Alcohol and Nonalcohol Related Liver Disease

Financial news for ARWR dated on 2019-12-13: Oppenheimer Initiates Coverage On Arrowhead Pharmaceuticals with Perform Rating

Financial news for ARWR dated on 2019-12-11: Arrowhead Pharmaceuticals Files IND For Phase 1b Study Of ARO-HIF2 For Treatment Of Clear Cell Renal Cell Carcinoma

Financial news for ARWR dated on 2019-12-10: Arrowhead Pharmaceuticals shares are trading higher. Not seeing any news to justify the price action.

Financial news for ARWR dated on 2019-12-04: 38 Stocks Moving In Wednesday's Mid-Day Session

Financial news for ARWR dated on 2019-12-04: 12 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for ARWR dated on 2019-12-04: 26 Stocks Moving in Wednesday's Pre-Market Session

Financial news for ARWR dated on 2019-12-04: Arrowhead Pharmaceuticals shares are trading lower after the company priced its 4 million share common stock offering at \$58 per share

Financial news for ARWR dated on 2019-12-04: Arrowhead Pharmaceuticals Prices 4M Share Offering of Common Stock at \$58.00/Share

Financial news for ARWR dated on 2019-12-04: 63 Biggest Movers From Yesterday

Financial news for ARWR dated on 2019-12-03: 40 Stocks Moving In Tuesday's Mid-Day Session

Financial news for ARWR dated on 2019-12-03: Arrowhead Pharmaceuticals shares are trading higher. Not currently seeing any news to justify the price action.

Financial news for ARWR dated on 2019-12-03: The Daily Biotech Pulse: Astellas To Buy Audentes For \$3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial

Financial news for ARWR dated on 2019-12-03: 19 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for ARWR dated on 2019-12-03: 22 Stocks Moving in Tuesday's Pre-Market Session

Financial news for ARWR dated on 2019-12-03: 75 Biggest Movers From Yesterday

Financial news for ARWR dated on 2019-12-03: 8 Stocks To Watch For December 3, 2019

Financial news for ARWR dated on 2019-12-02: Arrowhead Pharmaceuticals Announces A Proposed Underwritten Offering Of Its Common Stock

Financial news for ARWR dated on 2019-12-02: Shares of several healthcare stocks are trading lower as US equities dip following escalating US-China tensions over Hong Kong. US Stocks further fell on worse-than-expected manufacturing data.

Financial news for ARWR dated on 2019-12-02: Arrowhead Pharmaceuticals Option Alert: Jan 17 \$75 Calls at the Ask: 1000 @ \$5.5 vs 449 OI; Ref=\$66.9188

Financial news for ARWR dated on 2019-11-29: 7 Biggest Price Target Changes For Friday

Financial news for ARWR dated on 2019-11-27: Stocks That Hit 52-Week Highs On Wednesday

Financial news for ARWR dated on 2019-11-27: The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen

Financial news for ARWR dated on 2019-11-27: 60 Biggest Movers From Yesterday

Financial news for ARWR dated on 2019-11-26: Cantor Fitzgerald Says Arrowhead Pharmaceuticals May Be Worth \$75-\$90/Share In Sale

Financial news for ARWR dated on 2019-11-26: 38 Stocks Moving In Tuesday's Mid-Day Session

Financial news for ARWR dated on 2019-11-26: Stocks That Hit 52-Week Highs On Tuesday

Financial news for ARWR dated on 2019-11-26: Arrowhead Pharmaceuticals shares are trading higher after the company reported FY19 EPS and sales results are up from the same quarter last year.

Financial news for ARWR dated on 2019-11-26: The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug

Financial news for ARWR dated on 2019-11-26: 45 Biggest Movers From Yesterday

Financial news for ARWR dated on 2019-11-25: Arrowhead Pharmaceuticals FY19 EPS \$0.69 Up From \$(0.65) YoY, Sales \$168.796M Up From \$16.142M YoY

Financial news for ARWR dated on 2019-11-25: 33 Stocks Moving In Monday's Mid-Day Session

Financial news for ARWR dated on 2019-11-25: Stocks That Hit 52-Week Highs On Monday

Financial news for ARWR dated on 2019-11-25: Benzinga's Top Upgrades, Downgrades For November 25, 2019

Financial news for ARWR dated on 2019-11-25: 36 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for ARWR dated on 2019-11-25: Arrowhead Pharmaceuticals shares are trading higher after Baird upgraded the company's stock from Neutral to Outperform and raised the price target from \$39 to \$70.

Financial news for ARWR dated on 2019-11-25: 18 Stocks Moving In Monday's Pre-Market Session

Financial news for ARWR dated on 2019-11-25: Baird Upgrades Arrowhead Pharmaceuticals to Outperform, Raises Price Target to \$70

Financial news for ARWR dated on 2019-11-24: The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Arrowhead Earnings And More

Financial news for ARWR dated on 2019-11-20: The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data

Financial news for ARWR dated on 2019-11-19: Arrowhead Pharmaceuticals shares are trading higher after Cantor Fitzgerald maintained a Neutral rating on the stock and raised the price target from \$24 to \$50.

Financial news for ARWR dated on 2019-11-19: Stocks That Hit 52-Week Highs On Tuesday

Financial news for ARWR dated on 2019-11-19: Cantor Fitzgerald Maintains Neutral on Arrowhead Pharmaceuticals, Raises Price Target to \$50

Financial news for ARWR dated on 2019-11-15: 30 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for ARWR dated on 2019-11-14: Stocks That Hit 52-Week Highs On Thursday

Financial news for ARWR dated on 2019-11-14: The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing

Financial news for ARWR dated on 2019-11-13: Arrowhead Pharmaceuticals shares are trading higher after B. Riley FBR maintained a Buy rating on the stock and raised the price target from \$46 to \$59 per share.

Financial news for ARWR dated on 2019-11-13: Stocks That Hit 52-Week Highs On Wednesday

Financial news for ARWR dated on 2019-11-13: B. Riley FBR Maintains Buy on Arrowhead Pharmaceuticals, Raises Price Target to \$59

Financial news for ARWR dated on 2019-11-13: The Daily Biotech Pulse: Merck Goes Shopping, Nuvecra Files For Bankruptcy Protection, Opiant Rips Higher

Financial news for ARWR dated on 2019-11-12: Arrowhead Pharmaceuticals shares are trading higher. Not currently seeing any company-specific news.

Financial news for ARWR dated on 2019-11-12: Stocks That Hit 52-Week Highs On Tuesday

Financial news for ARWR dated on 2019-11-12: The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat

Financial news for ARWR dated on 2019-11-08: Arrowhead Pharma, J&J's Janssen To Present Phase 2 Data For Investigational Hep B Regimens At The Liver Meeting 2019

Financial news for ARWR dated on 2019-11-04: Stocks That Hit 52-Week Highs On Monday

Financial news for ARWR dated on 2019-11-04: Arrowhead Pharmaceuticals shares are trading lower. Not seeing any news to justify the price action.

Financial news for ARWR dated on 2019-10-31: The Daily Biotech Pulse: Agile Receives Favorable Adcom Verdict, Merit Medical Tumbles On Earnings, 2 Biotechs To Debut

Financial news for ARWR dated on 2019-10-30: Cramer Gives His Opinion On CyrusOne, CVS And More

Financial news for ARWR dated on 2019-10-24: Arrowhead Pharmaceuticals shares are

trading lower after Baird downgraded the company's stock from Outperform to Neutral and announced a \$39 price target.

Financial news for ARWR dated on 2019-10-24: Benzinga's Top Upgrades, Downgrades For October 24, 2019

Financial news for ARWR dated on 2019-10-24: Baird Downgrades Arrowhead Pharmaceuticals to Neutral, Announces \$39 Price Target

Financial news for ARWR dated on 2019-10-23: The Daily Biotech Pulse: Eli Lilly Revenues Trail Estimates, Moderna Gets Fast Track Designation, MacroGenics' Lukewarm Breast Cancer Data

Financial news for ARWR dated on 2019-10-22: Arrowhead Pharmaceuticals shares are trading higher after Chardan Capital maintained a Buy rating on the stock and raised the price target from \$32 to \$45.

Financial news for ARWR dated on 2019-10-22: Chardan Capital Maintains Buy on Arrowhead Pharmaceuticals, Raises Price Target to \$45

Financial news for ARWR dated on 2019-10-18: Stocks That Hit 52-Week Highs On Friday

Financial news for ARWR dated on 2019-10-18: Arrowhead Pharmaceuticals shares are trading higher after the company discussed its development strategy for its emerging pipeline of RNAi at its R&D conference.

Financial news for ARWR dated on 2019-10-18: 32 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for ARWR dated on 2019-10-18: The Daily Biotech Pulse: Intuitive Surgical Earnings, Paratek Pulls Out European Application For Antibiotic, Amgen's Evenity In Europe

Financial news for ARWR dated on 2019-10-17: Arrowhead Pharmaceuticals shares are trading higher. Not seeing any company-specific news to justify the price action.

Financial news for ARWR dated on 2019-10-03: Benzinga's Top Upgrades, Downgrades For October 3, 2019

Financial news for ARWR dated on 2019-10-03: 12 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for ARWR dated on 2019-10-03: Baird Initiates Coverage On Arrowhead Pharmaceuticals with Outperform Rating, Announces \$39 Price Target

Financial news for ARWR dated on 2019-09-30: Shares of Arrowhead Pharmaceuticals are trading higher. Not currently seeing any company-specific news.

Financial news for ARWR dated on 2019-09-16: 22 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for ARWR dated on 2019-09-16: Arrowhead Pharmaceuticals Presents Initial Top-Line Clinical Data and Preclinical Data on RNAi Candidates ARO-APOC3 and ARO-ANG3

Financial news for ARWR dated on 2019-09-15: The Week Ahead In Biotech: Novo Nordisk And Merck Await FDA Rulings, 2 IPOs On Deck

Financial news for ARWR dated on 2019-09-11: Arrowhead Pharmaceuticals shares are trading higher on seemingly no company specific news.

Financial news for ARWR dated on 2019-09-05: Arrowhead Pharma shares trading lower as the company presented at Citi's Annual Biotech Conference today.

Financial news for ARWR dated on 2019-09-05: Seeing Dip In Arrowhead Pharmaceuticals Shares; Co. Presenting At Citi Biotech Conference

Financial news for ARWR dated on 2019-08-28: Arrowhead Collaborator Janssen Begins REEF-1 Phase 2b Combination Study in Patients With Chronic Hepatitis B Infection; Arrowhead Earns \$25M Milestone Payment In Connection With Trial Initiation

Financial news for ARWR dated on 2019-08-22: The Daily Biotech Pulse: ViiV's Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrophin Flunks Late-Stage Study

Financial news for ARWR dated on 2019-08-20: The Daily Biotech Pulse: FDA Likes Nabriva's Antibiotic, Snubs Sarepta's DMD Drug; Moderna Gets Fast Track Designation For Zika Vaccine

Financial news for ARWR dated on 2019-08-19: Shares of several healthcare companies are trading higher as optimism increased for a resolution to the US-China trade war.

Financial news for ARWR dated on 2019-08-19: Stocks That Hit 52-Week Highs On Monday

Financial news for ARWR dated on 2019-08-19: 33 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for ARWR dated on 2019-08-16: Shares of healthcare companies are trading higher as US markets rebound from recent weakness following a yield curve inversion, which caused recession fears. Trump also recently announced the US would delay China tariffs, renewing hopes of a trade deal.

Financial news for ARWR dated on 2019-08-06: 28 Healthcare Stocks Moving In Today's Pre-Market Session

Financial news for ARWR dated on 2019-08-05: Arrowhead Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q3 EPS and sales results.

Financial news for ARWR dated on 2019-08-05: Arrowhead Pharmaceuticals Q3 EPS \$0.21 Misses \$0.29 Estimate, Sales \$46.7M Miss \$54.37M Estimate

Financial news for ARWR dated on 2019-07-16: Arrowhead Pharma shares are trading higher after the company reported it received Orphan Drug Designation for ARO-ANG3.

Financial news for ARWR dated on 2019-07-16: Arrowhead Pharma Reports Received Orphan Drug Designation For ARO-ANG3

Financial news for ARWR dated on 2019-07-01: 60 Biggest Movers From Friday

Financial news for ARWR dated on 2019-06-28: Arrowhead Pharmaceuticals shares are trading lower after Cantor Fitzgerald downgraded the stock from Overweight to Neutral.

Financial news for ARWR dated on 2019-06-28: 40 Stocks Moving In Friday's Mid-Day Session

Financial news for ARWR dated on 2019-06-28: Benzinga's Top Upgrades, Downgrades For June 28, 2019

Financial news for ARWR dated on 2019-06-28: Cantor Fitzgerald Downgrades Arrowhead Pharmaceuticals to Neutral

Financial news for ARWR dated on 2019-06-28: The Daily Biotech Pulse: Chiasma To Join R3K Index, EU Rejects Amgen's Osteoporosis Drug Application, Karuna IPO

Financial news for ARWR dated on 2019-06-27: Arrowhead Pharma Reports Received Fast Track Designation For ARO-AAT For Treatment Of Alpha-1 Liver Disease

Financial news for ARWR dated on 2019-06-21: Arrowhead Pharmaceuticals Receives FDA Orphan Drug Designation For ARO-APOC3 For The Treatment Of Familial Chylomicronemia Syndrome

Financial news for ARWR dated on 2019-06-19: The Daily Biotech Pulse: Positive Readouts From Adamas And Ironwood, Sesen Bio To Offer Shares, Stoke Therapeutics Debut

Financial news for ARWR dated on 2019-06-06: The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering

Financial news for ARWR dated on 2019-06-05: The Daily Biotech Pulse: Curtains Down On ASCO, Rewalk Flies, Eli Lilly's Migraine Drug Approved For Cluster Headache

Financial news for ARWR dated on 2019-05-29: The Daily Biotech Pulse: Inovio's Partner Scales Back R&D Collaboration, Genmab Seeks Nasdaq Listing, Bayer Gets Breakthrough Therapy Designation

Financial news for ARWR dated on 2019-05-28: 50 Biggest Movers From Friday

Financial news for ARWR dated on 2019-05-22: 50 Biggest Movers From Yesterday

Financial news for ARWR dated on 2019-05-21: 36 Stocks Moving In Tuesday's Mid-Day Session

Financial news for ARWR dated on 2019-05-21: Arrowhead Pharma shares trading higher following news the stock will join the S&P SmallCap 600 index.

Financial news for ARWR dated on 2019-05-21: 28 Stocks Moving In Tuesday's Pre-Market Session

Financial news for ARWR dated on 2019-05-21: The Daily Biotech Pulse: Setback For Merck In Breast Cancer Study, Arrowhead to Join S&P SmallCap 600 Index, Ocular's Glaucoma Trial Fails

Financial news for ARWR dated on 2019-05-20: S&P Dow Jones Indices Announces Kontoor Brands and Arrowhead Pharmaceuticals Set to Join S&P SmallCap 600; Kontoor To Replace Orion Group, Arrowhead To Replace Navigators

Financial news for ARWR dated on 2019-05-16: Shares of many Healthcare companies are trading higher as markets rebound from the recent volatility caused by uncertainty regarding US-China trade talks. Also, lawmakers were not able to pass a bill that would end 'surprise medical bills'.

Financial news for ARWR dated on 2019-05-08: Arrowhead Research Q2 EPS \$0.24 Beats \$0.19 Estimate, Sales \$48.148M Beat \$42.56M Estimate

Financial news for ARWR dated on 2019-05-08: The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split

Financial news for ARWR dated on 2019-05-02: Jim Cramer Weighs In On Exxon, Delta Air Lines And More

Financial news for ARWR dated on 2019-04-30: Shares of several healthcare companies are trading lower on continued uncertainty over healthcare policy as well as concerns over the medicare-for-all proposals among 2020 candidates.

Financial news for ARWR dated on 2019-04-24: Arrowhead Pharma Reports Commenced Triple Combo Cohort In Chronic HBV Patients, Earned \$25M Milestone Payment From J&J's Janssen

Financial news for ARWR dated on 2019-04-18: Shares of several healthcare companies are trading lower on continued weakness over concerns of 'Medicare for all' support within 2020 presidential candidates and the uncertainty over healthcare policy going into the election.

Financial news for ARWR dated on 2019-04-17: Shares of several healthcare companies are trading lower after Trump renewed his efforts to repeal and replace the Affordable Care Act; the Department of Justice moved to accelerate the appeal process in hopes to invalidate the ACA as unconstitutional.

Financial news for ARWR dated on 2019-04-15: Arrowhead Pharma Receives FDA Clearance for its Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease

Financial news for ARWR dated on 2019-04-12: Arrowhead Pharmaceuticals Highlights Presentation Of Clinical Data On JNJ-3989 (ARO-HBV) At International Liver Congress

Financial news for ARWR dated on 2019-04-12: Arrowhead Pharma Presented Preclinical Data Showing RNAi Therapy Prevents, Reverses Alpha-1 Liver Disease At Int'l. Liver Congress

Financial news for ARWR dated on 2019-03-18: Arrowhead Pharmaceuticals Files IND For Pivotal Phase 2/3 Study Of ARO-AAT For Treatment Of Alpha-1 Liver Disease

Financial news for ARWR dated on 2019-03-11: Arrowhead Pharma Begins Dosing for its Phase 1 Study of ARO-APOC3

Financial news for ARWR dated on 2019-02-11: 66 Biggest Movers From Friday

Financial news for ARWR dated on 2019-02-08: 48 Stocks Moving In Friday's Mid-Day Session

Financial news for ARWR dated on 2019-02-08: Arrowhead Pharmaceuticals shares are trading higher after the company reported Q1 EPS up 172.22% from last year, and sales up 887.46% from last year.

Financial news for ARWR dated on 2019-02-07: Arrowhead Research Q1 EPS \$0.13 May Not compare To \$0.54 Estimate, Sales \$34.66M May Not Compare To \$74.76M Estimate

Financial news for ARWR dated on 2019-02-07: The Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alector To Debut

Financial news for ARWR dated on 2019-02-03: The Week Ahead In Biotech: Conferences, Clinical Trials, Earnings And IPOs

Financial news for ARWR dated on 2019-01-07: Arrowhead Pharmaceuticals shares are trading higher after the company announced it began dosing in Phase 1 study of ARO-

ANG3.

Financial news for ARWR dated on 2019-01-07: Arrowhead Pharma Files for Regulatory Clearance to Begin Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia

Financial news for ARWR dated on 2018-12-17: Cantor Fitzgerald Maintains Overweight on Arrowhead Pharmaceuticals, Raises Price Target to \$165

Financial news for ARWR dated on 2018-12-13: 52 Biggest Movers From Yesterday

Financial news for ARWR dated on 2018-12-12: The Daily Biotech Pulse: Legal Victory For Boston Scientific, Alder Gets New CFO, FDA Go-Ahead For BioXcel

Financial news for ARWR dated on 2018-12-11: Arrowhead Pharma FY18 EPS \$(0.65) vs \$(0.47) In FY17, Sales \$16.142M vs \$31.408M In FY17

Financial news for ARWR dated on 2018-12-11: The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings

Financial news for ARWR dated on 2018-12-11: Earnings Scheduled For December 11, 2018

Financial news for ARWR dated on 2018-12-08: The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings

Financial news for ARWR dated on 2018-11-11: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for ARWR dated on 2018-10-19: Jim Cramer Shares His Thoughts On Amarin, AT&T, McDonald's And More

Financial news for ARWR dated on 2018-10-15: Arrowhead Pharmaceuticals Files For Regulatory Clearance To Begin Phase 1 Study Of ARO-ANG3

Financial news for ARWR dated on 2018-10-05: 45 Biggest Movers From Yesterday

Financial news for ARWR dated on 2018-10-04: Analysts React To Arrowhead's Janssen Collaboration: Downside In Stock May Be 'Misguided'

Financial news for ARWR dated on 2018-10-04: UPDATE: FBR B. Riley's Kumar Tells Benzinga Investors Are Likely 'Selling The News', Says Negative Sentiment May Be Misguided

Financial news for ARWR dated on 2018-10-04: Arrowhead Pharmaceuticals Shares Down 14.2%; FBR B. Riley's Madhu Kumar Tells Benzinga Investors Are Perceiving HBV Collab. With Janssen As Arrowhead 'Giving Away' Its Lead Asset, Making Co. Less Of An Acquisition Target

Financial news for ARWR dated on 2018-10-04: Arrowhead Announces \$3.7B License Agreement With Janssen For Gene-Silencing Drug

Financial news for ARWR dated on 2018-10-04: Arrowhead Pharmaceuticals On Conference Call Says Working On HBV With J&J, Not Going To Create A Competing HBV Product

Financial news for ARWR dated on 2018-10-04: Arrowhead Pharmaceuticals On Conference Call Says No Longer Dependent On Partnerships To Fund Rest Of Pipeline

Financial news for ARWR dated on 2018-10-04: Arrowhead Pharma Shares Resume Trade, Up 24%

Financial news for ARWR dated on 2018-10-04: Arrowhead Pharma Shares To Resume Trade At 7:50 a.m. EDT

Financial news for ARWR dated on 2018-10-04: UPDATE: Arrowhead Eligible To Receive Added \$3.5B In Potential Milestone Payments

Financial news for ARWR dated on 2018-10-04: UPDATE: Arrowhead Will Receive \$250M Upon Closing Of License, Collab Deal With J&J's Janssen

Financial news for ARWR dated on 2018-10-04: Arrowhead Reports \$3.7B License, Collaboration Deal With J&J's Janssen

Financial news for ARWR dated on 2018-10-04: Arrowhead Pharma Shares Halted News Pending

Financial news for ARWR dated on 2018-09-07: Stocks That Made New 52-Week Highs Yesterday, September 6th

Financial news for ARWR dated on 2018-09-07: The Daily Biotech Pulse: Amgen-AstraZeneca, Boston Scientific Opens Wallet, Advaxis Offering

Financial news for ARWR dated on 2018-09-07: 55 Biggest Movers From Yesterday

Financial news for ARWR dated on 2018-09-06: Mid-Afternoon Market Update: Crude Oil Down 1.2%; Cloudera Shares Climb On Upbeat Earnings

Financial news for ARWR dated on 2018-09-06: Arrowhead Pharmaceuticals shares are up 44.8% after the company earlier reported its ARO-HBV was well tolerated in HBV patients; Analysts at B. Riley FBR upgraded the stock from Neutral to Buy.

Financial news for ARWR dated on 2018-09-06: 40 Stocks Moving In Thursday's Mid-Day Session

Financial news for ARWR dated on 2018-09-06: Mid-Day Market Update: NASDAQ Down Over 1%; WSI Industries Shares Spike Higher

Financial news for ARWR dated on 2018-09-06: Mid-Morning Market Update: Markets Mixed; Navistar Profit Tops Estimates

Financial news for ARWR dated on 2018-09-06: Benzinga's Top Upgrades, Downgrades For September 6, 2018

Financial news for ARWR dated on 2018-09-06: B. Riley FBR Upgrades Arrowhead Pharmaceuticals to Buy

Financial news for ARWR dated on 2018-09-06: 21 Stocks Moving In Thursday's Pre-Market Session

Financial news for ARWR dated on 2018-09-06: Arrowhead Pharmaceuticals Says ARO-HBV Was Generally Well-Tolerated In HBV Patients, Says Up To 4.0 log10 Reduction In HBsAg Was Observed Following 3 Doses Of ARO-HBV

Financial news for ARWR dated on 2018-09-06: 54 Biggest Movers From Yesterday

Financial news for ARWR dated on 2018-09-05: 40 Stocks Moving In Wednesday's Mid-Day Session

Financial news for ARWR dated on 2018-09-05: 26 Stocks Moving In Wednesday's Pre-Market Session

Financial news for ARWR dated on 2018-08-31: Arrowhead Pharma Reports Completion Of Dosing In Phase 1 Study Of ARO-AAT For Treatment Of Alpha-1 Liver Disease

Financial news for ARWR dated on 2018-08-07: Arrowhead Research Q3 EPS \$(0.18), Inline, Sales \$727.375K Beat \$690K Estimate

Financial news for ARWR dated on 2018-08-07: The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmad's Antibiotic Faces FDA Panel

Financial news for ARWR dated on 2018-08-01: Arrowhead Pharmaceuticals Earns \$10M Milestone Payment From Amgen Following Administration Of First Dose Of AMG 890 In A Clinical Study

Financial news for ARWR dated on 2018-07-31: 50 Biggest Movers From Yesterday

Financial news for ARWR dated on 2018-07-30: Arrowhead Pharma Shares Down 12.4%; Some Speculate Amgen Head Of R&D Announcing On Fri. He's Leaving Amgen Could Have Implications For Arrowhead's Research Program For ARO-AMG1

Financial news for ARWR dated on 2018-07-30: 35 Stocks Moving In Monday's Mid-Day Session

Financial news for ARWR dated on 2018-07-30: Arrowhead Pharma Shares At Session Lows Down 20.4%; Not Seeing News To Justify Sharp Move Lower; Stock Broke Below Technical Level At \$16 Immediately After Mon. Open

Financial news for ARWR dated on 2018-07-25: Stocks Which Set New 52-Week High Yesterday, July 24th:

Financial news for ARWR dated on 2018-07-10: Benzinga's Daily Biotech Pulse: Acceleron On Fast Lane, OncoCyte's Accurate Diagnosis, Inspire Medical Gets Aetna Coverage

Financial news for ARWR dated on 2018-07-05: A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year

Financial news for ARWR dated on 2018-07-05: Benzinga's Daily Biotech Pulse: Realm Therapeutics To List On Nasdaq, CASI Pharma Added To Russell 2000 Index

Financial news for ARWR dated on 2018-07-03: Benzinga's Daily Biotech Pulse: Titan's Parkinson's Disease Drug Implant Trial, Juniper Pharma Sells Itself At 32% Premium

Financial news for ARWR dated on 2018-06-29: Arrowhead Pharma To Present New Preclinical, Initial Clinical Data On ARO-ATT At National Education Conference

Financial news for ARWR dated on 2018-06-27: Arrowhead Pharma Reports EMA's Committee For Orphan Medicinal Products Issued Positive Opinion On Co.'s Application For Orphan Designation Of ARO-AAT For Treatment Of Congenital Alpha-1 Antitrypsin Deficiency

Financial news for ARWR dated on 2018-06-20: Benzinga's Daily Biotech Pulse: Sarepta's DMD Gene Therapy, Anika's Flunked Trial, Eidos To Commence Trading

Financial news for ARWR dated on 2018-06-19: Benzinga's Daily Biotech Pulse: Biohaven Sells Right To Drug, Obseva To Sell Shares

Financial news for ARWR dated on 2018-06-19: 60 Biggest Movers From Yesterday

Financial news for ARWR dated on 2018-06-18: Arrowhead Pharmaceuticals On Monday Closed Up 23.8% After Co. Completed Enrollment in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease

Financial news for ARWR dated on 2018-06-18: Arrowhead Pharma Completes Enrollment in Phase 1 Study of ARO-AAT

Financial news for ARWR dated on 2018-06-14: Benzinga's Daily Biotech Pulse: FDA Nods For Teligent And Keytruda, Sonoma's Q4 Miss, Sage Inks Deal With Japan's Shionogi

Financial news for ARWR dated on 2018-05-31: Benzinga's Daily Biotech Pulse: Clinical Hold For Crispr, Gilead Study Meets Endpoint, Akers Gets Grace Time

Financial news for ARWR dated on 2018-05-30: Arrowhead Completes Enrollment in Single Dose Portion of Phase 1/2 Study of ARO-HBV

Financial news for ARWR dated on 2018-05-14: Arrowhead Doses First Hepatitis B Patients in Multiple Dose Portion of Phase 1/2 Study of ARO-HBV

Financial news for ARWR dated on 2018-05-10: Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results

Financial news for ARWR dated on 2018-05-10: 54 Biggest Movers From Yesterday

Financial news for ARWR dated on 2018-05-09: 48 Stocks Moving In Wednesday's Mid-Day Session

Financial news for ARWR dated on 2018-05-09: Benzinga's Top Upgrades, Downgrades For May 9, 2018

Financial news for ARWR dated on 2018-05-09: The Market In 5 Minutes: Iran Deal, Google's Virtual Assistant, Walmart-Flipkart

Financial news for ARWR dated on 2018-05-09: 22 Stocks Moving In Wednesday's Pre-Market Session

Financial news for ARWR dated on 2018-05-09: A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street

Financial news for ARWR dated on 2018-05-09: Cantor Fitzgerald Upgrades Arrowhead Pharmaceuticals to Overweight

Financial news for ARWR dated on 2018-05-08: Arrowhead Research Q2 EPS \$(0.18) Beats \$(0.19) Estimate, Sales \$650.125K Miss \$1.85M Estimate

Financial news for ARWR dated on 2018-05-08: Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure

Financial news for ARWR dated on 2018-05-06: The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Financial news for ARWR dated on 2018-03-27: 30 Stocks Moving In Tuesday's Mid-Day Session

Financial news for ARWR dated on 2018-03-27: Arrowhead Begins Dosing in Phase 1/2 Study of ARO-HBV for Treatment of Chronic Hepatitis B

Financial news for ARWR dated on 2018-03-27: Jefferies Initiates Coverage On Arrowhead Pharmaceuticals with Buy Rating, Announces \$10.00 Price Target

Financial news for ARWR dated on 2018-03-12: Arrowhead Begins Dosing in Phase 1 Study

of ARO-AAT for Treatment of Alpha-1 Liver Disease

Financial news for ARWR dated on 2018-02-27: 22 Stocks Moving In Tuesday's Pre-Market Session

Financial news for ARWR dated on 2018-02-27: 38 Biggest Movers From Yesterday

Financial news for ARWR dated on 2018-02-15: Arrowhead Pharma Release Confirms Earlier News Co. Received Orphan Drug Designation For ARO-AAT

Financial news for ARWR dated on 2018-02-15: Watching Arrowhead Pharma Shares As Traders Circulating FDA Orphan Drug Alert For ADS-001 RNA Interference-Based Liver Targeted Therapeutic

Financial news for ARWR dated on 2018-02-15: 22 Stocks Moving In Thursday's Pre-Market Session

Financial news for ARWR dated on 2018-02-15: Arrowhead Pharma Reports Received Regulatory Clearance To Begin Phase 1/2 Study Of ARO-HBV For Treatment Of Hep B

Financial news for ARWR dated on 2018-02-09: Arrowhead Pharma Reports Q1 EPS \$(0.18) From \$(0.17) YoY, Sales \$3.51M From \$4.37M YoY

Financial news for ARWR dated on 2018-02-09: Earnings Scheduled For February 9, 2018

Financial news for ARWR dated on 2018-01-18: Arrowhead Pharmaceuticals Prices 10M Share Offering At \$5.25/Share

Financial news for ARWR dated on 2018-01-18: 26 Stocks Moving In Thursday's Pre-Market Session

Financial news for ARWR dated on 2018-01-18: 10 Stocks To Watch For January 18, 2018

Financial news for ARWR dated on 2018-01-17: Arrowhead Pharma Reports Offering Of Common Stock, No Terms Disclosed

Financial news for ARWR dated on 2018-01-16: 38 Biggest Movers From Friday

Financial news for ARWR dated on 2018-01-12: 33 Stocks Moving In Friday's Mid-Day Session

Financial news for ARWR dated on 2018-01-05: B. Riley Initiates Coverage On Arrowhead Pharmaceuticals with Neutral Rating, Announces \$3.00 Price Target

Financial news for ARWR dated on 2018-01-04: Arrowhead Pharma Shares Continuing Higher Thurs. Following 25% Rally On Wed. After Price Broke Above \$4 Level; Stock Traded Over \$5 Level This Morning, Pulled Back From High; Not Seeing News To Justify Upside

Financial news for ARWR dated on 2018-01-04: 40 Biggest Movers From Yesterday

Financial news for ARWR dated on 2018-01-03: Arrowhead Pharma Shares Close Up 24.7% On No News, But Breakout Above \$4 Resistance Level; Stock Up 40+% Since Announcing Filing For Regulatory Clearance Of ARO-AAT, ARO-HBV On Dec. 20, Dec. 22, Respectively

Financial news for ARWR dated on 2017-12-28: Silence Therapeutics Liquidates Most of Stake in Arrowhead Pharmaceuticals

Financial news for ARWR dated on 2017-12-27: Arrowhead Pharma Names William Waddill As Independent Director On Board

Financial news for ARWR dated on 2017-12-26: 32 Stocks Moving In Tuesday's Pre-Market Session

Financial news for ARWR dated on 2017-12-26: 44 Biggest Movers From Friday

Financial news for ARWR dated on 2017-12-22: 36 Stocks Moving In Friday's Mid-Day Session

Financial news for ARWR dated on 2017-12-22: Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV

Financial news for ARWR dated on 2017-12-20: Arrowhead Pharma Reports Filing Of Regulatory Clearance To Commence Phase 1 Study Of ARO-AAT

Financial news for ARWR dated on 2017-12-14: 30 Biggest Movers From Yesterday

Financial news for ARWR dated on 2017-12-13: 32 Stocks Moving In Wednesday's Mid-Day Session

Financial news for ARWR dated on 2017-12-13: 30 Stocks Moving In Wednesday's Pre-Market Session

Financial news for ARWR dated on 2017-12-12: 8 Stocks Moving In Tuesday's After-Hours Session

Financial news for ARWR dated on 2017-12-12: Arrowhead Pharma Reports FY17 EPS \$(0.47) vs \$(1.34) In Same Qtr. Last Year, Sales \$31.408M vs \$158.3K YoY

Financial news for ARWR dated on 2017-12-12: Earnings Scheduled For December 12, 2017

Financial news for ARWR dated on 2017-12-06: Arrowhead Presents New Clinical Data Demonstrating a Sustained Host Response in Hepatitis B Patients Following RNAi Therapy

Financial news for ARWR dated on 2017-11-29: Seeing Notable Block Trade In Arrowhead Pharmaceuticals; 3.3M Shares At \$3.60 Blow Bid Of \$3.68

Financial news for ARWR dated on 2017-11-28: Piper Jaffray Healthcare Conference 2017 Begins Today, Presenters Include: Civitas Solutions, Insulet, ACADIA Healthcare, Nektar Therapeutics, Quidel, and Arrowhead Pharmaceuticals

Financial news for ARWR dated on 2017-11-27: Benzinga's Top Upgrades, Downgrades For November 27, 2017

Financial news for ARWR dated on 2017-11-27: PiperJaffray Upgrades Arrowhead Pharmaceuticals to Overweight

Financial news for ARWR dated on 2017-10-31: 28 Stocks Moving In Tuesday's Pre-Market Session

Financial news for ARWR dated on 2017-09-18: 12 Biggest Mid-Day Gainers For Monday

Financial news for ARWR dated on 2017-09-18: Benzinga's Top Upgrades, Downgrades For September 18, 2017

Financial news for ARWR dated on 2017-09-18: 22 Stocks Moving In Monday's Pre-Market Session

Financial news for ARWR dated on 2017-09-18: William Blair Upgrades Arrowhead Pharmaceuticals to Outperform

Financial news for ARWR dated on 2017-09-15: 18 Biggest Mid-Day Gainers For Friday

Financial news for ARWR dated on 2017-08-03: Arrowhead Reports Q3 EPS \$(0.07) vs \$(0.14) Est., Sales \$9.342M May Not Compare To \$5.13M Est.

Financial news for ARWR dated on 2017-05-04: Mid-Afternoon Market Update: Crude Oil Drops 5%; Alpha and Omega Semi Shares Gain On Earnings Beat

Financial news for ARWR dated on 2017-05-04: 20 Biggest Mid-Day Gainers For Thursday

Financial news for ARWR dated on 2017-05-04: Mid-Day Market Update: Crude Oil Down 4%; Insight Enterprises Shares Surge After Strong Q1 Results

Financial news for ARWR dated on 2017-05-04: Mid-Morning Market Update: Markets Edge Lower; Viacom Beats Q2 Expectations

Financial news for ARWR dated on 2017-05-03: Arrowhead Reports Q2 EPS \$(0.08) vs \$(0.12) Est., Sales \$8.986M May Not Compare To \$5.51M Est.

Financial news for ARWR dated on 2017-03-23: Arrowhead Pharma Adopts Shareholder Rights Agreement

Financial news for ARWR dated on 2017-02-22: Exclusive: Dicerna CEO Talks Goals For 2017, Competitors And Prospects Under Trump

Financial news for ARWR dated on 2017-02-06: Arrowhead Reports Q1 EPS \$(0.17) vs. Est. \$(0.20), Rev. \$4.3M

Financial news for ARWR dated on 2017-02-01: 22 Stocks Moving In Wednesday's Pre-Market Session

Financial news for ARWR dated on 2017-01-11: 15 Biggest Mid-Day Gainers For Wednesday

Financial news for ARWR dated on 2017-01-11: 22 Stocks Moving In Wednesday's Pre-Market Session

Financial news for ARWR dated on 2017-01-09: 15 Stocks Moving In Monday's Pre-Market Session

Financial news for ARWR dated on 2017-01-09: UPDATE: Silence Therapeutics Announces Acquisition of 8.4% Stake in Arrowhead; Says 'Recent Technological Advancements in RNA Therapeutics have been Underestimated and Undervalued'

Financial news for ARWR dated on 2017-01-09: Arrowhead Acknowledges 8.4% Stake by Silence Therapeutics

Financial news for ARWR dated on 2016-12-29: Arrowhead Pharmaceuticals Pops to High of \$1.66 on Volume

Financial news for ARWR dated on 2016-12-14: Arrowhead Reports FY16 EPS \$(1.34) vs. Prior Year Quarter \$(1.60)

Financial news for ARWR dated on 2016-12-14: Earnings Scheduled For December 14, 2016

Financial news for ARWR dated on 2016-12-01: 8-K from Arrowhead Pharma Shows Co. Notified Chief Scientific Officer, David Lewis, to Terminate

Financial news for ARWR dated on 2016-11-30: Mid-Afternoon Market Update: Arrowhead Pharma Tumbles Following EX-1 RNAi Program Discontinuations; Arbutus Biopharma Shares Surge

Financial news for ARWR dated on 2016-11-30: 18 Biggest Mid-Day Losers For Wednesday

Financial news for ARWR dated on 2016-11-30: Mid-Day Market Update: Crude Oil Up Over 8%; American Eagle Shares Plummet On Weak Guidance

Financial news for ARWR dated on 2016-11-30: Stocks Hitting 52-Week Lows

Financial news for ARWR dated on 2016-11-30: Mid-Morning Market Update: Markets Mostly Higher; GoPro To Reduce 15% Of Workforce

Financial news for ARWR dated on 2016-11-30: 10 Biggest Price Target Changes For Wednesday

Financial news for ARWR dated on 2016-11-30: Alnylam Is Now The Leader In The Clinical HBV RNAi Therapy Space

Financial news for ARWR dated on 2016-11-30: The Market In 5 Minutes: OPEC, Earnings And Trump's Cabinet

Financial news for ARWR dated on 2016-11-30: Benzinga's Top Downgrades

Financial news for ARWR dated on 2016-11-30: William Blair Downgrades Arrowhead Pharmaceuticals to Market Perform

Financial news for ARWR dated on 2016-11-30: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for ARWR dated on 2016-11-30: Arrowhead Pharma Downgraded Following EX-1 RNAi Program Discontinuations

Financial news for ARWR dated on 2016-11-30: PiperJaffray Downgrades Arrowhead Pharmaceuticals to Neutral

Financial news for ARWR dated on 2016-11-30: Cantor Fitzgerald Downgrades Arrowhead Pharmaceuticals to Hold

Financial news for ARWR dated on 2016-11-30: Chardan Capital Raises Price Target on Alnylam Pharma from \$73 to \$89 'In light of the removal of the Arrowhead programs from development'; Maintains Buy

Financial news for ARWR dated on 2016-11-30: Chardan Capital Downgrades Arrowhead Pharmaceuticals to Neutral

Financial news for ARWR dated on 2016-11-29: Arrowhead Pharma Shares Resume Trade, Now Down Nearly 70%

Financial news for ARWR dated on 2016-11-29: UPDATE: Arrowhead Pharma Says Will Reduce Workforce by ~30%

Financial news for ARWR dated on 2016-11-29: Arrowhead Pharma Shares to Resume Trade at 4:30 p.m. EDT

Financial news for ARWR dated on 2016-11-29: UPDATE: Arrowhead Cites Two Primary Reason for Discontinuation: 'became apparent that there would be substantial delays

in all clinical programs that utilize EX1,' Co.'s ' substantial advances in RNA chemistry and targeting'

Financial news for ARWR dated on 2016-11-29: Arrowhead To Discontinue Development Of Clinical State Drug Candidates ARC-520, ARC-521, and ARC-AAT

Financial news for ARWR dated on 2016-11-29: Arrowhead Shares Halted News Pending

Financial news for ARWR dated on 2016-11-09: Deaths Observed In Arrowhead Pharma's Clinical Study Don't Change Cantor's Buy Rating

Financial news for ARWR dated on 2016-11-09: 20 Biggest Mid-Day Losers For Wednesday

Financial news for ARWR dated on 2016-11-09: A Couple Of News Dumps You May Have Missed On Tuesday Night

Financial news for ARWR dated on 2016-11-09: Cantor Fitzgerald Analyst Reiterates Buy, \$15 Target on Arrowhead Pharma Following Clinical Hold News, 30% Decline in Stock Today

Financial news for ARWR dated on 2016-11-09: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for ARWR dated on 2016-11-08: Arrowhead Pharmaceuticals Says Notified Verbally By FDA of Decision to Place Clinical Hold On HeparC-2004

Financial news for ARWR dated on 2016-10-28: Arrowhead Pharmaceuticals Files For \$200M Mixed Shelf Offering

Financial news for ARWR dated on 2016-10-28: Selling Shareholder Amgen Selling 3M Shares Of Arrowhead Pharmaceuticals, Arrowhead Will Not Receive Any Proceeds From The Sale

Financial news for ARWR dated on 2016-10-27: 15 Stocks Which Plummeted Three Days On Increasing Volume

Financial news for ARWR dated on 2016-10-06: 18 Stocks Moving In Thursday's Pre-Market Session

Financial news for ARWR dated on 2016-09-30: 16 Stocks Moving In Friday's Pre-Market Session

Financial news for ARWR dated on 2016-09-29: 15 Biggest Mid-Day Gainers For Thursday

Financial news for ARWR dated on 2016-09-29: Arrowhead's Landmark Deal With Amgen Sends Shares Shooting Higher

Financial news for ARWR dated on 2016-09-29: Cantor Fitzgerald Analyst Reiterates Buy, \$15 Target on Arrowhead Pharma; Calls Deal with Amgen 'Landmark'

Financial news for ARWR dated on 2016-09-29: Mid-Morning Market Update: Markets Edge Lower; PepsiCo Beats Q3 Expectations

Financial news for ARWR dated on 2016-09-29: 15 Stocks Moving In Thursday's Pre-Market Session

Financial news for ARWR dated on 2016-09-29: Arrowhead Pharma Shares to Resume Trade at 8 a.m. EDT

Financial news for ARWR dated on 2016-09-29: UPDATE: Amgen Will Receive Global Exclusive License to Arrowhead's RNAi ARC-LPA Program

Financial news for ARWR dated on 2016-09-29: UPDATE: Arrowhead Will Receive \$56.5M in Upfront Payments, Up to Added \$617M in Potential Milestones

Financial news for ARWR dated on 2016-09-29: Amgen, Arrowhead Pharma Report Two Cardiovascular Collaborations

Financial news for ARWR dated on 2016-09-29: Arrowhead Pharma Shares Halted News Pending

Financial news for ARWR dated on 2016-09-07: Arrowhead Pharma Reports Dosing of First Patient with Hep B in Multiple Ascending Dose Portion of Phase 1/2 Study of ARC-521

Financial news for ARWR dated on 2016-09-06: Arrowhead Pharmaceuticals Begins Phase 2 Study of ARC-AAT

Financial news for ARWR dated on 2016-08-18: 15 Biggest Mid-Day Gainers For Thursday

Financial news for ARWR dated on 2016-08-18: Benzinga's Top Initiations

Financial news for ARWR dated on 2016-08-18: 20 Stocks Moving In Thursday's Pre-Market Session

Financial news for ARWR dated on 2016-08-18: Cantor Fitzgerald Initiates Coverage on Arrowhead Pharmaceuticals at Buy

Financial news for ARWR dated on 2016-08-17: Option Alert: ARWR Sep16 7.0 Calls: 1000 @ ASK \$0.30: 2004 traded vs 833 OI: \$6.25 Ref

Financial news for ARWR dated on 2016-08-10: Watch These 7 Huge Call Purchases In Wednesday Trade

Financial news for ARWR dated on 2016-08-09: After-Hours Losers Aug. 9, 2016: SPWR Down 29%, MYGN 23%, TDW 18.5%, YUME 10.2%, ARWR 9.2%, LSCC 8.6%, LOAN 8.5%, CYBR 6%

Financial news for ARWR dated on 2016-08-09: Arrowhead Pharmaceuticals Reports Q3 EPS \$(0.32) vs. Est. \$(0.37), Rev. \$39.58k vs. Est. \$60K

Financial news for ARWR dated on 2016-08-09: There Have Been 20 Secondary Offerings Over The Last 2 Days

Financial news for ARWR dated on 2016-08-09: Option Alert: ARWR Sep16 6.0 Calls Sweep: 3209 @ ASK \$0.50: 3215 traded vs 497 OI: Earnings today After Close \$5.63 Ref

Financial news for ARWR dated on 2016-08-09: Arrowhead Pharma Prices Offering of ~7.63M Shares at \$5.90/Share for Gross Proceeds \$45M

Financial news for ARWR dated on 2016-06-16: Arbutus Biopharma Taken Off Of Chardan's Sell List

Financial news for ARWR dated on 2016-06-09: Arrowhead Pharma Reports Initiation of Phase 1/2 Single, Multiple Dose Study of Hep B Candidate ARC-521

Financial news for ARWR dated on 2016-05-19: 5 Reasons Arrowhead Pharma Is A Hepatitis B Leader

Financial news for ARWR dated on 2016-05-19: The Market In 5 Minutes: The Oscars Of Fintech Is Coming

Financial news for ARWR dated on 2016-05-19: Chardan Capital Initiates Coverage on Arrowhead Pharmaceuticals at Buy, Announces \$12.00 PT

Financial news for ARWR dated on 2016-05-10: Arrowhead Reports Q2 EPS \$(0.35) vs. Est. \$(0.37), Rev. \$43K vs. Est. \$70K

Financial news for ARWR dated on 2016-05-06: Arrowhead Says ARC-LPA Achieved 98% Knockdown, Long Duration of Effect After Subcutaneous Admin

Financial news for ARWR dated on 2016-04-18: Arrowhead Pharmaceuticals Presents Preclinical Data on Renal Cell Carcinoma Program at AACR 2016

Financial news for ARWR dated on 2016-04-13: 10 Stocks Moving In Wednesday's Pre-Market Session

Financial news for ARWR dated on 2016-04-13: Arrowhead Announces ARC-520 Presentations To Be Made At ILC 2016, Data Found In Body

Financial news for ARWR dated on 2016-04-06: Arrowhead Research Changes Name to Arrowhead Pharmaceuticals

Financial news for ARWR dated on 2016-02-09: Arrowhead Reports Q1 EPS (\$0.32) vs. Est. (\$0.41), Rev. \$43.75 vs. Est. \$130K

Financial news for ARWR dated on 2016-01-19: Arrowhead Research Falls to Low of \$4.25 on Volume

Financial news for ARWR dated on 2016-01-19: Arrowhead ARC-AAT Granted EMA Orphan Drug Designation

Financial news for ARWR dated on 2016-01-07: Wayfair Launches Canadian Website, Wayfair.ca

Financial news for ARWR dated on 2016-01-07: Arrowhead Initiates Dosing For Phase 2b MONARCH Combo Study Of ARC-520 With Chronic HBV Infected Patients

Financial news for ARWR dated on 2015-12-14: Arrowhead Reports FY15 EPS \$(1.60),

Sales \$382K

Financial news for ARWR dated on 2015-12-07: Shares Of Arrowhead Up 12% On The Day With Positive Data On HBV Immune Reactivation In 7 Of 9 Immune Reactivation

Financial news for ARWR dated on 2015-12-01: Mid-Day Market Update: Breitburn Energy Partners Drops Following News of Distribution Suspension; Mattress Firm Shares Surge

Financial news for ARWR dated on 2015-11-16: Arrowhead Late-Breaking Clinical Data Shows that ARC-520 Can Produce Deep and Durable Reductions of Hepatitis B Viral Antigens and DNA

Financial news for ARWR dated on 2015-11-16: US Stock Futures Edge Higher Ahead Of Empire State Manufacturing Index

Financial news for ARWR dated on 2015-11-15: Arrowhead Presents Positive Data on ARC-520 in Hepatitis B Infected Chimpanzees at AASLD Liver Meeting 2015

Financial news for ARWR dated on 2015-10-13: Benzinga's Top #PreMarket Gainers

Financial news for ARWR dated on 2015-09-28: 10 Stocks Moving In Monday's After-Hours Session

Financial news for ARWR dated on 2015-09-25: 'We're Confident Arrowhead's ARC-520 Is Active Drug For HBV,' Piper Jaffray Says

Financial news for ARWR dated on 2015-09-25: Morning Market Gainers

Financial news for ARWR dated on 2015-09-25: Benzinga's Top #PreMarket Gainers

Financial news for ARWR dated on 2015-09-24: Mid-Morning Market Update: Markets Tumble; Accenture Tops Q4 Estimates

Financial news for ARWR dated on 2015-09-24: Morning Market Gainers

Financial news for ARWR dated on 2015-09-24: Benzinga's Top #PreMarket Gainers

Financial news for ARWR dated on 2015-09-24: Arrowhead Research +25% Premarket Following Announcement of Results of ARC-520 Hep B Study

Financial news for ARWR dated on 2015-09-24: Arrowhead Research Announces Peak Reduction in HBsAg of Up to 99% Following Single Dose of ARC-520 for Naive Cohort

Financial news for ARWR dated on 2015-09-11: Morning Market Gainers

Financial news for ARWR dated on 2015-09-11: Arrowhead +10% Premarket as Co Nominates ARC-HIF2 as First RNAi Therapeutic Candidate Using Extrahepatic DPC Delivery System

Financial news for ARWR dated on 2015-09-11: Arrowhead Nominates ARC-HIF2 As First RNAi Therapeutic Candidate Using Extrahepatic DPC Delivery System

Financial news for ARWR dated on 2015-08-26: 4 Biotechs Piper Jaffray Is Buying On The Pullback

Financial news for ARWR dated on 2015-07-08: Arrowhead Announces Recieved Regulatory Clearance for ARC-AAT Phase 1 in UK, New Zealand

Financial news for ARWR dated on 2015-07-02: Arrowhead Initiates Dosing of ARC-AAT in Patients with Alpha-1 Antitrypsin Deficiency

Financial news for ARWR dated on 2015-06-17: Arrowhead Receives Regulatory Clearance to Begin Additional Phase 2b Studies of Hepatitis B Candidate ARC-520

Financial news for ARWR dated on 2015-06-10: Arrowhead Gets Orphan Drug Designation for ARC-AAT

Financial news for ARWR dated on 2015-05-11: Arrowhead Research Reports Q2 Loss \$0.51 Vs Est Loss \$0.34, Sales \$43.750K Vs Est \$110.0K

Financial news for ARWR dated on 2015-05-06: Arrowhead Presents Data on Potential RNAi Candidate Targeting Factor 12 Mediated Angioedemic and Thromboembolic Diseases

Financial news for ARWR dated on 2015-05-05: Arrowhead Finishes Dosing Healthy Volunteers and Initiates Transition to Patients in Phase 1 Study of ARC-AAT

Financial news for ARWR dated on 2015-04-14: Analyst Wants Proof On Arrowhead Research's Hepatitis B Drug

Financial news for ARWR dated on 2015-04-14: Morning Market Losers

Financial news for ARWR dated on 2015-04-14: Benzinga's Top #PreMarket Losers

Financial news for ARWR dated on 2015-04-14: Jefferies Downgrades Arrowhead Research to Hold

Financial news for ARWR dated on 2015-04-13: Morning Market Gainers

Financial news for ARWR dated on 2015-04-13: Benzinga's Top #PreMarket Gainers

Financial news for ARWR dated on 2015-04-13: Arrowhead Research Announces Cleared to Proceed with Multiple Dose Phase 2b Study of ARC-520

Financial news for ARWR dated on 2015-04-01: Option Alert: Arrowhead Research Apr \$8 Call; 5149 Contract Trade above Ask @\$0.29; Now \$7.38

Financial news for ARWR dated on 2015-03-05: Arrowhead Research Soars After Acquiring Novartis' RNAi Portfolio

Financial news for ARWR dated on 2015-03-05: Morning Market Gainers

Financial news for ARWR dated on 2015-03-05: Benzinga's Top #PreMarket Gainers

Financial news for ARWR dated on 2015-02-10: The News That Should Move Arrowhead Research Today

Financial news for ARWR dated on 2015-02-09: Arrowhead Research Reports Q1 Loss of \$0.41/Share vs Loss of \$0.34/Share Est.

Financial news for ARWR dated on 2015-02-02: Arrowhead Research Shares Seeing Significant Short Interest

Financial news for ARWR dated on 2015-01-22: Deutsche Bank Downgrades Arrowhead, Says 2015 Is The 'Show-Me Year'

Financial news for ARWR dated on 2015-01-22: Deutsche Bank Downgrades Arrowhead Research to Hold, Lowers PT to \$7.00

Financial news for ARWR dated on 2015-01-12: Mid-Day Market Update: Foundation Medicine Shares Jump Following Deal With Roche; Crude Oil Slides Over 4%

Financial news for ARWR dated on 2015-01-12: Mid-Morning Market Update: Markets Tumble; Shire To Acquire NPS Pharmaceuticals For \$5.2 Billion

Financial news for ARWR dated on 2015-01-12: Morning Market Losers

Financial news for ARWR dated on 2015-01-12: Merger Monday Moving Stocks Monday Morning

Financial news for ARWR dated on 2015-01-12: Arrowhead Research Tumbles 20% Following FDA News

Financial news for ARWR dated on 2015-01-12: Benzinga's Top #PreMarket Losers

Financial news for ARWR dated on 2015-01-12: Arrowhead Research Says FDA Informed Co in Preliminary Call of Partial Clinical Hold Under Which Co Cleared to Begin Modified Study of ARC-520

Financial news for ARWR dated on 2015-01-02: Benzinga's Top #PreMarket Gainers

Financial news for ARWR dated on 2014-12-31: Biotech Stocks Make Big Moves In Final Days Of 2014

Financial news for ARWR dated on 2014-12-30: Option Alert: Arrowhead Research Jan \$10 Call: 1,283 Contracts Traded vs 1 OI; Currently \$8.37

Financial news for ARWR dated on 2014-12-15: Arrowhead Reports Filing of IND for RNAi Therapeutic ARC-520 for Commencement of Phase 2b Multiple-Dose Studies in Chronic Hep B Patients

Financial news for ARWR dated on 2014-11-25: 8-K from Arrowhead Shows FY14 Loss of \$1.25/Share vs Loss of \$1.05/Share Est.

Financial news for ARWR dated on 2014-11-18: Arrowhead Files For Regulatory Permission To Begin Phase 1 Trial Of RNAi Therapeutic ARC-AAT

Financial news for ARWR dated on 2014-11-10: Shares of Arrowhead Resources Move Higher on Report CEO to be on CNBC

Financial news for ARWR dated on 2014-11-10: Arrowhead Offers Data on ARC-520, ARC-AAT at AASLD The Liver Meeting

Financial news for ARWR dated on 2014-10-14: 13G Filing from QVT Financial on Arrowhead Research Shows Raised Stake from 3.44% as of Jun. 30 to 7.62%

Financial news for ARWR dated on 2014-10-14: The 3 Most Volatile Biotech Stocks

Financial news for ARWR dated on 2014-10-09: Arrowhead Issues Open Letter to Shareholders

Financial news for ARWR dated on 2014-10-08: RBC Capital Downgrades Arrowhead Research Corporation to Sector Perform, Lowers PT to \$9.00

Financial news for ARWR dated on 2014-10-08: Arrowhead Research Corp Hammered On Drug News; Deutsche Bank Lowers Price Target

Financial news for ARWR dated on 2014-10-08: Midday Losers From October 8 - Arrowhead Research Corp, A10 Networks Inc. And More

Financial news for ARWR dated on 2014-10-08: Deutsche Bank on Arrowhead: 'We see higher risk but do not think program is dead,' Price Target Slashed from \$45 to \$20

Financial news for ARWR dated on 2014-10-08: Hearing Deutsche Bank Defending Arrowhead Research

Financial news for ARWR dated on 2014-10-08: Hearing Jefferies Defends Arrowhead Research

Financial news for ARWR dated on 2014-10-08: Arrowhead Research Corp Down Big On Disappointing Hepatitis B Drug Data

Financial news for ARWR dated on 2014-10-08: Shares of Arrowhead Research Halted on Fourth Circuit Breaker, Now Down 42%

Financial news for ARWR dated on 2014-10-08: Arrowhead Research Shares Resume Trade, Now Down ~45.5%

Financial news for ARWR dated on 2014-10-08: Arrowhead Research Shares Halted on Third Circuit Breaker, Now Down ~48.7%

Financial news for ARWR dated on 2014-10-08: Shares of Arrowhead Research Resume, Now Down ~45%

Financial news for ARWR dated on 2014-10-08: Shares of Arrowhead Research Halted on Second Circuit Breaker, Now Down ~38%

Financial news for ARWR dated on 2014-10-08: Adam Feuerstein @adamfeuerstein Tweet: In case you're wondering, \$ARWR selling off bc ARC-520 HepB data in #AASLD14 abstract just released are disappointing. Details

Financial news for ARWR dated on 2014-10-08: Arrowhead Research Halted

Financial news for ARWR dated on 2014-10-08: Arrowhead to Present ARC-520 Phase 2a Data in Late-Breaking Session at AASLD Liver Meeting 2014

Financial news for ARWR dated on 2014-10-08: Morning Market Losers

Financial news for ARWR dated on 2014-10-08: Benzinga's Top #PreMarket Losers

Financial news for ARWR dated on 2014-10-06: Top 5 Biotech Stocks Over The Past Year

Financial news for ARWR dated on 2014-09-22: UPDATE: Arrowhead Research Spokesperson Says Spike in Share Price Most Likely Due to Submission of Late Breaking Abstract for AASLD Meeting, But that Was Already Known

Financial news for ARWR dated on 2014-09-22: UPDATE: Hearing Move in Arrowhead Research May be Attributed to Positive News Regarding Hep B Drug

Financial news for ARWR dated on 2014-09-22: Arrowhead Research Spikes Higher

Financial news for ARWR dated on 2014-09-04: Arrowhead Research Corp Heads Higher After Breakout

Financial news for ARWR dated on 2014-09-03: Arrowhead Research Corp Shares Push Over Resistance Level As Momentum Continues

Financial news for ARWR dated on 2014-08-26: Winners & Losers From Tuesday, August 26

Financial news for ARWR dated on 2014-08-26: Deutsche Bank Sees Achillion, Arrowhead As Potential Takeover Targets

Financial news for ARWR dated on 2014-08-12: Arrowhead Research Corporation Reports Q2 EPS of \$(0.22), Inline

Financial news for ARWR dated on 2014-07-29: Morning Market Movers

Financial news for ARWR dated on 2014-07-29: Benzinga's Top #PreMarket Gainers

Financial news for ARWR dated on 2014-07-09: Arrowhead Research Up Over 6% Following CNBC Comments

Financial news for ARWR dated on 2014-07-08: Arrowhead Research Spikes Higher on Positive CNBC Comments

Financial news for ARWR dated on 2014-06-30: 4 Biotech Stocks With Big Money Coming In

Financial news for ARWR dated on 2014-06-19: Benzinga's Top #PreMarket Losers

Financial news for ARWR dated on 2014-06-13: Arrowhead Offers Statement on IP for ARC-520, Does Not Expecting ARC-520 Commercialization Infringing Patents

Financial news for ARWR dated on 2014-06-13: Option Alert: Arrowhead Research Jun \$11 Call; 2,064 Contract Trade Between Bid and Ask vs 627 OI; Currently \$11.57

Financial news for ARWR dated on 2014-05-27: Mid-Afternoon Market Update: S&P Looks To Close At All-Time High As Analogic Takes A Hit On Preliminary Results

Financial news for ARWR dated on 2014-04-16: Mid-Afternoon Market Update: Markets Trade Up as Bank of America Shares Remain Down

Financial news for ARWR dated on 2014-04-16: Mid-Day Market Update: Yahoo Jumps On Upbeat Results; ASML Shares Decline

Financial news for ARWR dated on 2014-04-15: Mid-Afternoon Market Update: Markets Trade in Highly Volatile Session as Talk of a Pull-Back is Widespread

Financial news for ARWR dated on 2014-04-09: Amended 13G Filing from Point72 Asset Mgmt on Arrowhead Research Shows 7.1% Stake

Financial news for ARWR dated on 2014-03-25: Deutsche Bank Remains Positive on Arrowhead Research Despite Weakness

Financial news for ARWR dated on 2014-03-24: Deutsche Bank Defends Arrowhead Amid ~16% Decline, Reiterates Buy

Financial news for ARWR dated on 2014-03-24: Arrowhead Begins Dosing in Phase 2a Trial of RNAi Therapeutic ARC-520 in Chronic Hepatitis B Patients

Financial news for ARWR dated on 2014-03-05: UPDATE: Soaring 19%, Deutsche Bank Initiates Coverage on Arrowhead Research

Financial news for ARWR dated on 2014-03-05: UPDATE: Deutsche Bank Initiates Coverage on Arrowhead Research on Good Potential

Financial news for ARWR dated on 2014-03-05: Benzinga's Volume Movers

Financial news for ARWR dated on 2014-03-05: Mid-Morning Market Update: Markets Mostly Flat; Brown-Forman Posts Higher Profit

Financial news for ARWR dated on 2014-03-05: Morning Movers for Mar. 5, 2014: FCEL, ARWR, SWHC, CPST Moving Higher

Financial news for ARWR dated on 2014-03-05: UPDATE: RBC Capital Sees Arrowhead Research Potentially Attractive M&A, Partnering Interest from Bristol, Merck, Novartis

Financial news for ARWR dated on 2014-03-05: Benzinga's Top #PreMarket Gainers

Financial news for ARWR dated on 2014-03-05: Benzinga's Top Initiations

Financial news for ARWR dated on 2014-03-05: Deutsche Bank Initiates Coverage on Arrowhead Research Corporation at Buy, Announces \$45.00 PT

Financial news for ARWR dated on 2014-03-04: After-Hours Movers: BV, SWHC, AVAV, CTIC Moving Higher, HCI, BOBE, CHEF, THOR Lower

Financial news for ARWR dated on 2014-03-04: RBC Capital Initiates Coverage on Arrowhead Research Corporation at Outperform, Announces \$35.00 PT

Financial news for ARWR dated on 2014-03-03: Benzinga's Top Initiations

Financial news for ARWR dated on 2014-03-03: Barclays Initiates Coverage on Arrowhead Research Corporation at Overweight, Announces \$32.00 PT

Financial news for ARWR dated on 2014-03-03: Arrowhead Receives Regulatory Approval to Begin Phase 2a Trial of Chronic Hepatitis B Candidate ARC-520

Financial news for ARWR dated on 2014-02-19: UPDATE: Arrowhead Announces Pricing of Underwritten 5.5M Share Offering of Common Stock at \$18.95 per Share

Financial news for ARWR dated on 2014-02-19: Arrowhead Prices 5.5M Shares at \$18.95/Share

Financial news for ARWR dated on 2014-02-18: Arrowhead Announces Proposed Underwritten Offering of Common Stock; Size Not Stated

Financial news for ARWR dated on 2014-02-13: This Week's Sector Gainers And Losers

Financial news for ARWR dated on 2014-02-13: ETF Outlook For Thursday, February 13, 2014 (XSD, VNM, PXN, COPX)

Financial news for ARWR dated on 2014-02-04: Arrowhead Research Corporation Reports Q1 EPS of \$(0.28) vs \$(0.20) Est

Financial news for ARWR dated on 2013-12-18: Jefferies Initiates Coverage on Arrowhead Research Corporation at Buy, Announces \$15.00 PT

Financial news for ARWR dated on 2013-12-18: Earnings Scheduled For December 18, 2013

Financial news for ARWR dated on 2013-12-09: Arrowhead Issues Phase 1 Data on ARC-520 at HepDART '13

Financial news for ARWR dated on 2013-11-25: Arrowhead Pharma Submits Application to Begin Phase 2A Trial of ARC-520

Financial news for ARWR dated on 2013-10-21: Benzinga's Top Initiations

Financial news for ARWR dated on 2013-10-21: Piper Jaffray Initiates Coverage on Arrowhead Research Corporation at Overweight, Announces \$12.00 PT

Financial news for ARWR dated on 2013-10-14: Arrowhead Priced 3.07M Shares at \$5.86/Share

Financial news for ARWR dated on 2013-10-08: Arrowhead Prices Offering at \$5.86/Share for Net Proceeds of \$60M

Financial news for ARWR dated on 2013-08-07: Arrowhead Research Corporation Reports Q3 EPS of \$(0.23)

Financial news for ARWR dated on 2013-07-23: Arrowhead Begins Phase 1 Trial of RNAi Therapeutic ARC-520 for Treatment of Chronic Hepatitis B Infection

Financial news for ARWR dated on 2013-05-28: Arrowhead Files to Begin Phase 1 Trial of RNAi Therapeutic

Financial news for ARWR dated on 2013-05-09: Arrowhead Research Corporation Reports Q2 EPS of \$(0.41)

Financial news for ARWR dated on 2013-04-29: UPDATE: Arrowhead Prices \$36M Private Offering at \$1.83 per Share

Financial news for ARWR dated on 2013-04-29: Arrowhead Prices \$36M Private Offering

Financial news for ARWR dated on 2013-03-25: Arrowhead to Host Analyst Event Today to Discuss Chronic Hepatitis B Treatment

Financial news for ARWR dated on 2013-02-28: Arrowhead Wins Notice of Patent Allowance for New Protease Sensitive Masking Chemistry for DPC siRNA Delivery System

Financial news for ARWR dated on 2013-02-26: Benzinga's Small Cap Movers for Tuesday February 26 2013

Financial news for ARWR dated on 2013-01-25: Arrowhead Research Prices 1.65M Units at \$2.12/Unit

Financial news for ARWR dated on 2013-01-24: Arrowhead Announces Proposed Stock, Warrants Offering

Financial news for ARWR dated on 2012-12-20: Arrowhead Research Corporation Reports Q4 EPS of \$(0.43)

Financial news for ARWR dated on 2012-12-18: Arrowhead and Shire Enter into Collaboration and License Agreement to Develop Peptide-Targeted Therapeutics

Financial news for ARWR dated on 2012-12-07: Arrowhead Prices 1.8M Units at \$2.26/Unit

Financial news for ARWR dated on 2012-12-06: Arrowhead Research Corporation Announces Proposed Public Offering of Common Stock and Warrants

Financial news for ARWR dated on 2012-10-16: Arrowhead Research Receives Notice of Patent Allowance for New Formulation of DPC siRNA Delivery System Showing 500-Fold Increase in Potency

Financial news for ARWR dated on 2012-10-11: Stocks Hitting 52-Week Lows

Financial news for ARWR dated on 2012-08-14: A Peek Into The Market Before The Trading Starts

Financial news for ARWR dated on 2012-08-14: Arrowhead Enters into Antibody Candidate Evaluation Agreement with Merck

Financial news for ARWR dated on 2012-08-13: Arrowhead Research Corporation Reports Q3 EPS \$-0.71; Revenues \$47,917

Financial news for ARWR dated on 2012-08-13: Arrowhead Sells 2.3M Shares, 1.7M Warrants for \$6.2M

Financial news for ARWR dated on 2012-07-11: Arrowhead Pops 7% on First Patient Dosing of Adipotide

Financial news for ARWR dated on 2012-07-11: A Peek Into The Market Before The Trading Starts

Financial news for ARWR dated on 2012-07-11: Arrowhead Announces Dosing of First Patient with Anti-Obesity Treatment Adipotide(r) in a Phase 1 Clinical Trial

Financial news for ARWR dated on 2012-06-26: Arrowhead Announces New Study Demonstrating Rapid Improvement in Pro-Diabetic Metabolic Markers with Anti-Obesity Drug Candidate, Adipotide(r)

Financial news for ARWR dated on 2012-06-06: Arrowhead Research Advances ARC-520 into IND-Enabling Studies for the Treatment of Hepatitis B and Provides Guidance on Development Timeline

Financial news for ARWR dated on 2012-05-25: 4 Smaller Alternatives to Big Pharma Obesity Treatments

Financial news for ARWR dated on 2012-04-11: Arrowhead Research Corporation Acquires Alvos Therapeutics and Proprietary Library of Targeting Peptides

Financial news for ARWR dated on 2012-03-07: A Peek Into The Market Before The Trading Starts

Financial news for ARWR dated on 2012-03-07: Arrowhead Releases White Paper on Hepatitis B Virus and Potential RNAi Treatment

Financial news for ARWR dated on 2012-03-07: Arrowhead Releases White Paper on Hepatitis B Virus and Potential RNAi Treatment

Financial news for ARWR dated on 2012-03-05: Arrowhead Research Corporation and Axolabs GmbH Enter into Strategic Alliance and Master Services Agreement for RNAi Therapeutics

Financial news for ARWR dated on 2012-01-05: Alnylam and Arrowhead Form Collaboration and Licensing Agreement

Financial news for ARWR dated on 2012-01-04: Arrowhead Announces FDA Clearance to Initiate Adipotide Phase I Clinical Trial

Financial news for ARWR dated on 2011-11-16: Arrowhead Research Announces 1-for-10 Reverse Stock Split

Financial news for ARWR dated on 2011-11-10: Arrowhead Research Hits New 52-Week

High, \$1.19

Financial news for ARWR dated on 2011-11-10: Arrowhead Research Spiking Higher on Heavy Volume

Financial news for ARWR dated on 2011-11-10: Arrowhead Research Subsidiary Ablaris Therapeutics Data Published in Science Translational Medicine Demonstrates Weight Loss in Obese Monkeys

Financial news for ARWR dated on 2011-11-02: Vascular Research Further Validates the Drug Development Programs of Arrowhead Research Subsidiary Ablaris Therapeutics and Alvos Therapeutics

Financial news for ARWR dated on 2011-10-27: Arrowhead Research Appoints Bruce Given M.D. Chief Operating Officer

Financial news for ARWR dated on 2011-10-24: Arrowhead Research Corporation Acquires Roche RNA Assets and Site

Financial news for ARWR dated on 2011-10-04: Arrowhead Research Corporation Completes \$5.5 Million Private Placement

Financial news for ARWR dated on 2011-07-29: Arrowhead Research Making Late-Day Run

Financial news for ARWR dated on 2011-07-26: The Next Big Breakout Stock

Financial news for ARWR dated on 2011-06-09: Arrowhead Receives Additional 180 Day Grace Period to Comply with the NASDAQ \$1.00 Minimum Bid Requirement

Financial news for ARWR dated on 2011-05-09: Top Chemical Manufacturing Stocks pick to buy- FSI, VHI, SMG, LXU, TNH, SHI, BAK, CF, RTK, GRA, NANX...

Financial news for ARWR dated on 2011-02-10: Arrowhead Reports Q1 EPS of \$(0.02)

Financial news for ARWR dated on 2011-01-18: Arrowhead Increases Investment in Calando Pharmaceuticals

Financial news for ARWR dated on 2011-01-04: 8 Penny Stocks Get Delisting Warning

Financial news for ARWR dated on 2010-12-22: Arrowhead Reports Revenue of \$181k

Financial news for ARWR dated on 2010-12-09: Arrowhead CEO Comments on \$4.5M Alliance Between Unidym and Samsung Electronics

Financial news for ARWR dated on 2010-10-27: NanoIntegris and Unidym Execute Global Distribution Agreement

Financial news for ARWR dated on 2010-09-29: Arrowhead CEO Provides Update on Company Strategy

Financial news for ARWR dated on 2010-08-12: Arrowhead Reports Fiscal 2010 Third Quarter Financial Results

Financial news for ARWR dated on 2010-04-27: Stocks That Crossed 52-Week Highs (ALXA, AETI, ARWR, CALP, CAVM)